Navigation Links
Sirion Therapeutics Announces Clinical Data to be Presented at the,2007 Association for Research in Vision and Ophthalmology (ARVO),Annual Meeting

TAMPA, Fla., April 23, 2007 /PRNewswire/ -- Sirion Therapeutics announced today that data on two of the Company's pipeline compounds, ST-601 (difluprednate) and ST-602 (fenretinide), will be presented at the 2007 annual meeting of The Association for Research in Vision and Ophthalmology (ARVO) in Ft. Lauderdale, FL. In addition to these presentations, the company will be hosting a reception for ARVO attendees.

ST-601 (difluprednate) is currently being evaluated in two phase III clinical trials in the treatment of ocular inflammation following cataract surgery. ST-601 (difluprednate) was acquired by Sirion last year through an exclusive licensing agreement with Senju Pharmaceutical Co., LTD of Japan. The agreement gives Sirion the U.S. rights to develop and market a topical ophthalmic emulsion containing the steroid compound difluprednate for the treatment of inflammatory eye diseases and conditions.

ST-602 (fenretinide) is currently being evaluated in a phase II clinical trial in the treatment of Geographic Atrophy (GA) in patients with age-related macular degeneration. The trial is a multicenter, randomized, double-masked, placebo controlled, dose-comparison in up to 225 patients in approximately 20 sites in the United States.

"We are pleased to announce the upcoming schedule of presentations relating to difluprednate and fenretinide at the ARVO annual conference. ARVO is the one of the oldest, largest and most highly respected vision research organizations in the world," stated Barry Butler, President and Chief Executive Officer of Sirion Therapeutics. "This is exciting news for our company in that it is the first time we will be presenting scientific data on our pipeline compounds. These presentations will provide support of the potential future clinical utility of these compounds in the treatment of ophthalmic eye diseases and conditions and demonstrate our commitment to discovering, de veloping and commercializing ophthalmic therapies for unmet needs."

    Sirion Therapeutics Reception for all ARVO attendees:


    A company update and presentation by Sirion Therapeutics' senior

    executives

    Date: Tuesday, May 8, 2007, 7:30 p.m. -- 9:00 p.m.

    Venue: Ft. Lauderdale Grande

    For additional information, contact Mary Leaper at

     or register online at

    www.siriontherapeutics.com/ARVO and use the password VISION.



    ARVO poster presentations featuring ST-601 (difluprednate):


    Preclinical Pharmacokinetics of Difluprednate Emulsion

    Session Date: Tuesday, May 8, 2007, 8:30 a.m. - 10:15 a.m.

    Posterboard Number: B741, Program Number: 2651


    Ocular Distribution and Metabolism after Instillation of Difluprednate

     Ophthalmic Emulsion in Rabbits

    Session Date: Tuesday, May 8, 2007, 8:30 a.m. - 10:15 a.m.

    Posterboard Number: B744, Program Number: 2654


    Preclinical Toxicity of Difluprednate Emulsion

    Session Date: Tuesday, May 8, 2007, 8:30 a.m. - 10:15 a.m.

    Posterboard Number: B743, Program Number: 2653


    Efficacy of Difluprednate Ophthalmic Emulsion in Preclinical Studies of

     Uveitis

    Session Date: Tuesday, May 8, 2007, 8:30 a.m. - 10:15 a.m.

    Posterboard Number: B742, Program Number: 2652


    Difluprednate Emulsion Inhibits Postoperative Inflammation in Rabbit

     Paracentesis Model

    Session Date: Tuesday, May 8, 2007, 8:30 a.m. - 10:15 a.m.

    Posterboard Number: B745, Program Number: 2655


    A Phase III, Non-Inferiority Study of Difluprednate Ophthalmic Emulsion

     (DFBA), 0.05% in the Treatment of Anterior Uveitis

    Session Date: Wednesday, May 9, 2007, 8:30 a.m. - 10:15 a.m.

    Posterboard Number: B808, Program Number: 3904


    A Phase III, Open-Label, Clinical Study of Difluprednate Ophthalmic

     Emulsion (DFBA), 0.05% in the Treatment of Severe Refractory Anteri
or

     Uveitis

    Session Date: Wednesday, May 9, 2007, 8:30 a.m. - 10:15 a.m.

    Posterboard Number: B809, Program Number: 3905


    Efficacy and Safety Results of a Phase III Study of Difluprednate

     Ophthalmic Emulsion 0.05% in Postoperative Inflammation

    Session Date: Wednesday, May 9, 2007, 8:30 a.m. - 10:15 a.m.

    Posterboard Number: B807 , Program Number: 3903


    ARVO poster presentations featuring ST-602 (fenretinide):


    Reduction of Serum Retinol Binding Protein Arrests the Accumulation of

     Toxic Retinal Fluorophores: A Nonpharmacological Approach

    Session Date: Tuesday, May 8, 2007, 3:00 p.m. - 4:45 p.m.

    Posterboard Number: B220, Program Number: 3244


    Megalin and Related Endocytic Receptors Mediate Uptake of Retinoid Binding

     Proteins in the Retinal Pigment Epithelium

    Session Date: Tuesday, May 8, 2007, 3:00 p.m. - 4:45 p.m.

    Posterboard Number: B221, Program Number: 3245

mleaper@siriontherapeutics.com

About Sirion Therapeutics, Inc.

Sirion Therapeutics is an ophthalmic biopharmaceutical company poised to compete in the $4 billion U.S. prescription ophthalmic market segment. Sirion is dedicated to the development and commercialization of innovative products to address unmet clinical needs. The company is currently developing a portfolio of product candidates that includes therapies in the areas of inflammatory diseases and conditions, allergy, dry eye, herpetic keratitis and dry age-related macular degeneration. Sirion is focused on growth through in- licensing, acquisition and geographic expansion. For more information regarding Sirion, please visit Sirion's website at http://www.siriontherapeutics.com.

CONTACT: Penny Cobb, of Sirion Therapeutics, Inc., +1-813-496-7325 x221, pcob b@siriontherapeutics.com

Web site: http://www.siriontherapeutics.com/http://www.siriontherapeutics.com/ARVO/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
10. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
11. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... Calif. , March 1, 2017   Sun Chlorella ... about all things chlorella, is pleased to announce Non-GMO Project ... premium chlorella powder. Just in time for the ... in Anaheim, CA , Sun Chlorella Corp. ... all chlorella products, including: Sun Chlorella ...
(Date:3/1/2017)... 2017  Integrated Modular Design (IMD), a ... implementation of pre-fabricated healthcare products like bathroom ... seeks to lead the construction industry toward ... Fueled by their leading-edge pre-fabrication solutions, ... construction timelines and project risk, and increasing ...
(Date:3/1/2017)... 1, 2017  Global biotherapeutics leader CSL Behring ... ever Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) trial, known as ... reatment with H izentra ® ).  The Phase ... safety and tolerability of two different doses of CSL ... Subcutaneous [Human]), compared with placebo, in the maintenance treatment ...
Breaking Medicine Technology:
(Date:3/1/2017)... ... March 01, 2017 , ... ... permanently embedded anti-odor solution to cotton knit and woven fabrics. , Retail ... maintaining the luxurious look and feel of cotton. Cotton Incorporated has developed ...
(Date:3/1/2017)... HILLS, CA (PRWEB) , ... March 01, 2017 , ... ... cryoablation for the treatment of early stage breast cancer and where it fits in ... Genes & The Choices We Make .” The event brings together leading cancer and ...
(Date:3/1/2017)... ... March 01, 2017 , ... Expert on international living and leading a ... & Go. , Time & Go app is the ultimate strategic compass that helps ... time management methods enable people to work smarter, not harder, that's why Time & ...
(Date:3/1/2017)... York, NY & Greenwich, CT (PRWEB) , ... March 01, 2017 ... ... many runners, especially in the winter months when people don’t want to stop training ... the knees – and setting the treadmill to a small incline can help protect ...
(Date:3/1/2017)... ... March 01, 2017 , ... “McFarnia”: a suspenseful tale of ... truth about his life and mysterious disappearance. “McFarnia” is the creation of published author ... North Carolina. He currently serves as a Chaplain with Transport for Christ at a ...
Breaking Medicine News(10 mins):